Story · Medicine & Biotech
FDA Adds Another Player in ALK-Positive Lung Cancer
4 outlets · first reported by The ASCO Post on · latest · 34 hours of coverage
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded... (MedPage Today)
Coverage, in order
-
FDA Grants Accelerated Approval to Neladalkib for ALK -Positive NSCLC
Today, neladalkib (Nelkarmi), a kinase inhibitor, was granted accelerated approval for adults with previously treated, locally advanced or metastatic ALK -positive non–small cell lung cancer (NSCLC).
-
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer
-
FDA Adds Another Player in ALK-Positive Lung Cancer(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...
-
FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung CancerThe US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi) on November 17, 2026, for adults with previously treated, locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.